Low doses in immunotherapy: Are they effective?
| Autor: | Vijay M Patil, Vanita Noronha, Amit Joshi, Anuja Abhyankar, Nandini Menon, Shripad Banavali, Sudeep Gupta, Kumar Prabhash |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Cancer Research, Statistics, and Treatment, Vol 2, Iss 1, Pp 54-60 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2590-3233 2590-3225 45640696 |
| DOI: | 10.4103/CRST.CRST_29_19 |
| Popis: | Checkpoint inhibitors are versatile immunomodulatory agents, and they are being approved for the treatment of an increasing number of cancers, based on the demonstration of clinical benefits. While they have changed the landscape of treatment of many cancers, they remain inaccessible to most patients, especially in low-income countries because of their prohibitive costs. Conventionally, chemotherapy drug doses are decided based on the maximum tolerable dose in phase 1 studies, but this dose-finding methodology is not applicable to targeted therapies where dose-limiting toxicity is not reached at doses much higher than sufficiently active doses. This review article focuses on how lower doses of immunotherapy drugs could be as efficacious as the currently recommended doses, thus decreasing the financial burden. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|